文献速递骨质疏松与钙磷/甲状旁腺

散发性甲状旁腺腺瘤中GCM2激活型序列变异的分析

Analysis of Activating GCM2 Sequence Variants in Sporadic Parathyroid Adenomas.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

本研究对396例散发性甲状旁腺腺瘤患者进行GCM2激活型变异测序,发现CCID变异(p.V382M和p.Y394S)占1.52%,非CCID变异(p.Y282D)占5.05%,总频率6.57%,约为一般人群的三倍,但外显率低。

要点

  • 散发性甲状旁腺腺瘤中GCM2激活型变异总频率为6.57%。
  • CCID变异p.V382M和p.Y394S见于1.52%的腺瘤。
  • 非CCID变异p.Y282D见于5.05%的腺瘤,外显率低。

核心结论

  • GCM2的CCID变异在散发性甲状旁腺腺瘤患者中富集,可能中度增加散发性孤立性甲状旁腺腺瘤风险。
  • 这些变异外显率低,大多数携带者不会发生散发性甲状旁腺腺瘤。

研究设计与样本

  • 对396例未选择的散发性甲状旁腺腺瘤病例的基因组DNA进行PCR扩增和测序,检测编码甲状旁腺功能亢进相关激活型GCM2变异的区域。

主要发现

  • 在396例腺瘤中,6例(1.52%)检出激活型GCM2 CCID变异(p.V382M和p.Y394S)。
  • 20例腺瘤(5.05%)检出甲状旁腺功能亢进相关的GCM2非CCID激活型变异(p.Y282D)。
  • 本研究中检测的激活型GCM2变异总体频率为6.57%,约为一般人群频率的三倍。

临床怎么用

  • 对于散发性甲状旁腺腺瘤患者,可考虑GCM2激活型变异的检测,但需注意外显率低,多数携带者不会发病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Sporadic, solitary parathyroid adenoma is the most common cause of primary hyperparathyroidism (PHPT). Apart from germline variants in certain cyclin-dependent kinase inhibitor genes and occasionally in MEN1, CASR, or CDC73, little is known about possible genetic variants in the population that may confer increased risk for development of typical sporadic adenoma. Transcriptionally activating germline variants, especially within in the C-terminal conserved inhibitory domain (CCID) of glial cells missing 2 (GCM2), encoding a transcription factor required for parathyroid gland development, have recently been reported in association with familial and sporadic PHPT. OBJECTIVE: To evaluate the potential role of specific GCM2 activating variants in sporadic parathyroid adenoma. DESIGN AND PATIENTS: Regions encoding hyperparathyroidism-associated, activating GCM2 variants were PCR amplified and sequenced in genomic DNA from 396, otherwise unselected, cases of sporadic parathyroid adenoma. RESULTS: Activating GCM2 CCID variants (p.V382M and p.Y394S) were identified in six of 396 adenomas (1.52%), and a hyperparathyroidism-associated GCM2 non-CCID activating variant (p.Y282D) was found in 20 adenomas (5.05%). The overall frequency of tested activating GCM2 variants in this study was 6.57%, approximately threefold greater than their frequency in the general population. CONCLUSIONS: The examined, rare CCID variants in GCM2 were enriched in our cohort of patients and appear to confer a moderately increased risk of developing sporadic solitary parathyroid adenoma compared with the general population. However, penetrance of these variants is low, suggesting that the large majority of individuals with such variants will not develop a sporadic parathyroid adenoma.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Riccardi A, Aspir T, Shen L, et al. Analysis of Activating GCM2 Sequence Variants in Sporadic Parathyroid Adenomas. J Clin Endocrinol Metab. 2019. PMID: 30624640. doi:10.1210/jc.2018-02517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。